Intra-Cellular Therapies Inc. said underwriters of its public offering fully exercised their option to buy an additional 1,451,613 shares at $15.50 apiece.

Gross proceeds from the offering, including the overallotment option, were about $172 million, with net proceeds of about $162 million.

The closing of the sale of shares in relation to the overallotment option was completed Oct. 5.

J.P. Morgan Securities LLC and Leerink Partners LLC acted as joint book-running managers. Cantor Fitzgerald & Co. acted as lead manager and Canaccord Genuity Inc., BTIG LLC and Ladenburg Thalmann & Co. Inc. acted as co-managers for the offering.